S
Silvio Danese
Researcher at Humanitas University
Publications - 1184
Citations - 47449
Silvio Danese is an academic researcher from Humanitas University. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 90, co-authored 893 publications receiving 35801 citations. Previous affiliations of Silvio Danese include The Catholic University of America & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Axel Dignass,G. Van Assche,James O. Lindsay,Marc Lémann,Johan D. Söderholm,Jean-Frederic Colombel,Silvio Danese,André D'Hoore,Miquel A. Gassull,Fernando Gomollón,Daan W. Hommes,Pierre Michetti,Colm O'Morain,Tom Øresland,Alastair Windsor,Eduard F. Stange,Simon Travis +16 more
TL;DR: This paper is the second in a series of three publications relating to the European evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the management of active disease, maintenance of medically induced remission and surgery.
Journal ArticleDOI
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
Journal ArticleDOI
Epithelial NEMO links innate immunity to chronic intestinal inflammation
Arianna Nenci,Christoph Becker,Andy Wullaert,Ralph Gareus,Geert van Loo,Silvio Danese,Marion Huth,Alexei Nikolaev,Clemens Neufert,Blair B. Madison,Deborah L. Gumucio,Markus F. Neurath,Manolis Pasparakis +12 more
TL;DR: It is demonstrated that a primary NF-κB signalling defect in intestinal epithelial cells disrupts immune homeostasis in the gastrointestinal tract, causing an inflammatory-bowel-disease-like phenotype.
Journal ArticleDOI
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn,Chinyu Su,Bruce E. Sands,Geert R. D'Haens,Severine Vermeire,Stefan Schreiber,Silvio Danese,Brian G. Feagan,Walter Reinisch,Wojciech Niezychowski,Gary S. Friedman,Nervin Lawendy,Dahong Yu,Deborah A Woodworth,Arnab Mukherjee,Haiying Zhang,Paul J. Healey,Julián Panés +17 more
TL;DR: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo and was associated with increased lipid levels.